North Andover, Massachusetts, USA (February 1, 2013) – During the recent Meeting of the Board
of Directors of Bach Pharma, Inc., Chairman of the Board Dr. Steven L. Stroup announced the
appointment of Mr. Daniel Cato of Durham, North Carolina to the position of President of Bach
Pharma, Inc. Mr. Cato has served as a Director of Bach Pharma for the past year in addition to serving
the position of Vice President of International Regulatory Affairs.
Mr. Cato is a Director and the Vice President of Project Operations for Cato Research Ltd.
headquartered in Durham, North Carolina. Mr. Cato is also the Managing Director for Cato Research
Washington located in Rockville, Maryland, where he is in close contact with the FDA and other Federal
US agencies. Dan is also on the Board of Directors of Cato Holding Company, Ltd, located in Durham,
North Carolina. In addition, he is a Director and the Secretary/Treasurer of the RTP Federal Credit
Union in North Carolina, with over 12,000 members and $104 million in assets.
Dan received his BS and MS in electrical engineering from North Carolina State University, and
continued on to receive his MBA with an emphasis in health care from Duke University, Fuqua School
of Business Global Executive Program, the world’s first global MBA program for senior executives. Dan
brings with him over 20 years of experience in corporate management and pharmaceutical clinical trial
management and research.
Bach Pharma CEO, Mr. Mark O. Henry, said, “Dan will undoubtedly continue to be a tremendous help
to Bach Pharma. His experience in the area of regulatory affairs and clinical trials combined with his
overall management experience will greatly add to Bach’s management team.”
About Bach Pharma
Bach Pharma, Inc., based in North Andover, MA is a pharmaceutical company engaged in the
discovery, development, and commercialization of new therapeutics for the treatment of life
threatening oxidative stress related diseases as well as other serious illnesses. Bach is a member of
the US-Russian Chamber of Commerce of New England and pioneered the founding of the US-Russian
Scientific Exchange Forum. The Foundation for the National Institutes of Health (FNIH), in partnership
with the National Institutes of Health (NIH), the Institute of Medicine (IOM) and the Russian Academy
of Sciences (RAS) of the Russian Federation, was created as a result of the 2009 U.S.-Russia Bi-
Lateral Presidential Commission, which highlighted greater cooperation in the health sciences as a key
theme. The Forum promotes and facilitates broader research collaboration in the biomedical and
behavioral sciences between the U.S. and Russian scientific communities, with the goal of improving
public health. Specifically, the Forum will strengthen joint research activities related to disease control,
treatment and prevention, clinical and translational research, regulatory science, and the development
of new health technologies.
Incorporated in 2001, Bach developed the proprietary manufacturing technologies for its proven
phthalazinedione drug platform, and owns all of the intellectual property that encompasses this entire
class of phthalazinediones as pharmaceutical agents. Monosodium Luminol is a subclass of
phthalazinediones. Bach maintains one of the world’s most active monosodium luminol research
programs focused on specific compound platforms and their derivates.
Bach is an enthusiastic member of the MassBio Council, Advancing Massachusetts Biotechnology for
worldwide medical benefits, and a proud host company of the Massachusetts Life Sciences Center
Internship Challenge Program.
About Cato Research Ltd
Cato Research is a contract research organization (CRO) providing a complete range of services
specializing in innovative development strategies for pharmaceutical and biotechnology companies
through all stages of the clinical development process. Cato Research has strategic offices through-out
the world, including Tel Aviv, Israel, Fourways, South Africa, and Quebec, Canada. Cato Research is a
strategic alliance partner and CRO for Bach Pharma with offices located in the Bay Colony Corporate
Center in Waltham, Massachusetts.
For more information about Cato Research companies please visit their main website www.cato.com,
contact them by telephone 919.361.CATO (2286), or email email@example.com.
For additional information about Bach Pharma please visit their website at www.bachpharma.com,
contact them by telephone 978.794.5510, or email firstname.lastname@example.org.
For information about this press release please contact Dr. Norman Spencer at: